Robust Covariate Adjustment in Multi-Center Randomized Trials
多中心随机试验中的稳健协变量调整AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接研究随机试验中的反事实均值、平均处理效应及协变量调整,因此归入因果推断。
多中心随机试验中的稳健协变量调整AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Augmented inverse probability weighting and G-computation with canonical generalized linear models have become increasingly popular for estimating the average treatment effect (ATE) in randomized experiments. These methods leverage outcome prediction models to adjust for imbalances in baseline covariates across treatment arms, improving power compared to unadjusted analyses, while controlling Type I error, even when models are misspecified. In multi-center trials they are often implemented without accounting for clustering by centers. We investigate how ignoring center-level correlation can impair estimation, degrade coverage of confidence intervals, and obscure interpretation. We find these issues to be especially acute for estimators of counterfactual means, as shown through simulations and clarified via theoretical arguments. To address these challenges, we develop semiparametric efficient estimators of counterfactual means and ATE defined for a randomly sampled center and patient. These estimators leverage outcome prediction models to improve efficiency yet retain large-sample unbiasedness under model misspecification. We further introduce an inference framework, inspired by random-effects meta-analysis, tailored to settings with many small centers. Incorporating center effects into the prediction models yields substantial efficiency gains, particularly when treatment effects vary across centers. Simulations and application to the WASH Benefits Bangladesh trial illustrate strong finite-sample performance of the proposed methods.